Medicine and Dentistry
Therapeutic Procedure
100%
Inpatient
51%
Neoplasm
45%
Immunotherapy
31%
Malignant Neoplasm
29%
Diseases
28%
Infection
17%
Nodular Melanoma
17%
T Cell
16%
Radiation Therapy
15%
Heart Failure
15%
Evaluation Study
15%
Follow up
14%
Overall Survival
14%
Breast Cancer
12%
Clinical Trial
12%
Hemochromatosis
12%
Nonalcoholic Fatty Liver
11%
Adverse Event
10%
Biological Marker
10%
COVID-19
9%
Symptoms
9%
Quality of Life
9%
Surgery
9%
Oncology
8%
Injury
8%
Multiple Sclerosis
8%
Prevalence
7%
Immune Response
7%
Iron Overload
7%
Arm
7%
Liver Disease
7%
Recurrent Disease
7%
Non Small Cell Lung Cancer
7%
Solid Malignant Neoplasm
7%
Liver Transplantation
7%
Percutaneous Aortic Valve Replacement
6%
Human Immunodeficiency Virus
6%
Pembrolizumab
6%
Hazard Ratio
6%
Percutaneous Coronary Intervention
6%
Head and Neck Cancer
6%
Odds Ratio
6%
Bleeding
6%
Clinician
5%
Biopsy
5%
Head and Neck Squamous Cell Carcinoma
5%
Neck
5%
Hemodynamic
5%
Surgeon
5%
Cytotoxic T-Cell
5%
Neonatal Intensive Care Unit
5%
Liver Cirrhosis
5%
Motivation
5%
Health Care Cost
5%
Primary Health Care
5%
Combination Therapy
5%
Nivolumab
5%
Drug Therapy
5%
Mental Health
5%
Cardiogenic Shock
5%
Progression Free Survival
5%
Tumor Microenvironment
5%
Colon Cancer
5%
Left Ventricular Assist Device
5%
Immunology and Microbiology
T Cell
50%
Immunotherapy
30%
Mouse
24%
Cytotoxic T-Cell
16%
Immune Response
16%
T-Helper Cell
14%
Monospecific Antibody
10%
Cytokine
9%
Agonist
9%
Tumor Cell
9%
Macrophage
8%
Regulatory T Cell
8%
Lymphocyte
8%
CD4
8%
T Cell Receptor
8%
Tumor Antigen
7%
Dendritic Cell
7%
Overall Survival
7%
Vaccine Efficacy
6%
Immunocompetent Cell
6%
CD8
6%
Cancer Immunotherapy
6%
Head
6%
Interferon Type I
6%
Programmed Death-Ligand 1
5%
Tumor-Infiltrating Lymphocytes
5%
Neoantigen
5%
Neck
5%
Antigen Specificity
5%
Monoclonal Antibody
5%
Adaptive Immune System
5%
Lymph Node
5%
Squamous Cell
5%
Tumor Immunity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
33%
Diseases
24%
Malignant Neoplasm
21%
Infection
18%
Immunotherapy
15%
Adverse Event
15%
Clinical Trial
13%
Melanoma
12%
Solid Malignant Neoplasm
11%
Overall Survival
10%
Multiple Sclerosis
9%
Placebo
8%
Chemotherapy
8%
Nephrotoxicity
8%
Gentamicin
8%
Nonalcoholic Fatty Liver
8%
Interferon
7%
Ribavirin
7%
Mouse
7%
Non Small Cell Lung Cancer
7%
Breast Cancer
7%
Progression Free Survival
6%
Pembrolizumab
6%
Biological Marker
6%
Receptor
6%
Ipilimumab
5%
Chronic Hepatitis C
5%
Inflammation
5%
Liver Cirrhosis
5%
Heart Failure
5%
Antiinfective Agent
5%
Liver Disease
5%
Chronic Hepatitis B
5%
CD8 Antigen
5%
Nivolumab
5%
Hepatitis C
5%